Shares of Thermo Fisher Scientific Inc (NYSE:TMO, ETR:TN8) jumped nearly 12% on Wednesday morning after the company reported second-quarter results that topped Wall Street estimates, fueled by strong demand across its life sciences and diagnostics segments.
The company posted revenue of $10.86 billion, surpassing analysts’ expectations of $10.69 billion and marking a 3% year-over-year increase.
Organic revenue rose 2%, beating estimates of 0.8%. Adjusted earnings per share came in at $5.36, ahead of the expected $5.24, while adjusted operating income grew to $2.38 billion from $2.35 billion a year ago.
Thermo Fisher highlighted a series of strategic product developments during the quarter, including the launch of advanced mass spectrometry systems—Orbitrap Astral Zoom, Excedion Pro, and Krios 5 Cryo-TEM—as well as an expanded DynaDrive bioreactor line. The company also announced that its Accelerator Drug Development solution was validated by a Tufts Center study and noted the acquisition of Sanofi’s Ridgefield site to enhance US sterile fill-finish capabilities.
“Our exceptional team continues to execute at a high level, enabling customer success while navigating the macroenvironment,” said CEO Marc Casper. “The trusted partner status and agility of our PPI Business System help us adapt, manage costs, and gain market share.”
Casper added the company remains on track to meet its 2025 commitments and is “building a brighter future for Thermo Fisher.”